←Back to Expert Scholars
Translational Medicine / 转化医学Regulatory T Cells, CCR4 Mogamulizumab
Hiroyoshi Nishikawa
MD, PhD
🏢National Cancer Center Japan🌐Japan
Chief, Division of Cancer Immunology
80
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Hiroyoshi Nishikawa defined effector Treg subsets in human tumors and pioneered targeting CCR4+ effector Treg with mogamulizumab to enhance antitumor immunity. His clinical-translational work at the Japanese National Cancer Center has established Treg depletion as a viable immuno-oncology strategy.
Share:
🧪Research Fields 研究领域
CCR4 Treg depletion
mogamulizumab cancer
effector Treg
tumor infiltrating Treg
combination immunotherapy
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Hiroyoshi Nishikawa 的研究动态
Follow Hiroyoshi Nishikawa's research updates
留下邮箱，当我们发布与 Hiroyoshi Nishikawa（National Cancer Center Japan）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment